Tinengotinib is named as a drug or biological intervention in 4 clinical trials in our China, UK and USA trial registers, 2 of which are recruiting. Lead sponsors include TransThera Sciences (Nanjing), Inc. (3) and Akeso (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Cholangiocarcinoma; Hepatocellular Carcinoma (HCC); Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07052253 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. (ClinicalTrials.gov ↗) Hepatocellular Carcinoma (HCC) |
Phase 2 | Recruiting |
| NCT07498478 | Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (ClinicalTrials.gov ↗) Breast Cancer |
Phase 2 | Recruiting |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma Cholangiocarcinoma |
Phase 3 | Active, closed |
| NCT06057571 | Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor (ClinicalTrials.gov ↗) Cholangiocarcinoma Metastatic |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Cholangiocarcinoma | 1 |
| Hepatocellular Carcinoma (HCC) | 1 |
| Breast Cancer | 1 |
| Cholangiocarcinoma Metastatic | 1 |
| Lead sponsor | Trials |
|---|---|
| TransThera Sciences (Nanjing), Inc. | 3 |
| Akeso | 1 |
| Register | Tinengotinib trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tinengotinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tinengotinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.